Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT02952339 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

NIH

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV LID ΔM2-2 1030s vaccine
BIOLOGICAL: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)